Indian pharma stocks bled on July 22, with Nifty Pharma sliding nearly 2% after President Trump announced tariffs of up to 200% on imported generic drugs. The plan starts at 0% from August 1, 2026, ramping to 200% over two years. Panic selling hit Sun Pharma, Dr. Reddy's, Lupin, and Cipla indiscriminately. But a closer look at company filings reveals a more nuanced picture: several Indian pharma majors have been quietly building US manufacturing capacity for years. The real question isn't who gets hurt — it's who's already prepared.

The Companies With American Plants

Aurobindo Pharma is perhaps the most exposed to US tariffs — its US formulation business contributes around 85% of total revenue, per its Q2 FY24 earnings call. But it's also among the best prepared. Per its May 2026 earnings call, the company's Dayton facility "has transitioned into the commercial phase with manufacturing underway," while its Raleigh facility awaits regulatory clearance. Management stated these US facilities position the company to "touch the $2 billion revenue milestone" in the US over the near term. If the tariff targets imports specifically, drugs manufactured domestically would be exempt — and Aurobindo is already producing on American soil. Zydus Lifesciences derives 46% of consolidated revenues from the US — the highest exposure among major Indian pharma companies — and distributes over 200 generic products there, per its annual report. But Zydus moved early: it acquired two biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for US$75 million upfront plus US$50 million in contingent payments. Per its investor presentation, this gives Zydus "immediate access to advanced biologics manufacturing capabilities" on US soil — a hedge that looks prescient given today's tariff announcement. Cipla has grown its North America franchise to nearly $1 billion annually ($934 million), per its latest earnings call, where management noted overall revenue grew 8% and EBITDA expanded 14%. Cipla operates 46 cGMP-compliant manufacturing facilities across five countries, per its annual report, including a facility in Hauppauge, New York. That US footprint could prove critical as tariffs escalate over the next two years.

The Ones Facing Headwinds

Sun Pharma, India's largest pharma company, reported US sales of $473 million in a single quarter, accounting for 29.3% of consolidated sales, per its quarterly earnings call. Its innovative medicines portfolio in the US crossed $1 billion for the first time — now larger than its US generics business. While Sun Pharma operates 41 manufacturing facilities across six continents, a US$11.7 million restructuring charge for US operations flagged in its quarterly results suggests ongoing adjustments. The silver lining: Sun Pharma's pivot toward innovative (patented) medicines could provide a natural buffer, since tariffs specifically target generic imports. Lupin delivered a strong turnaround, with North America revenue growing 16% and the US specifically growing 17% to $235 million in Q3 FY25, per its earnings call. Full-year gross margins improved sharply from 68.8% to 72.3%. But unlike Aurobindo or Zydus, Lupin's filings don't highlight significant US manufacturing facilities. Its growth has come primarily from complex generics and new product launches exported from India — exactly the business model the tariff threatens. Dr. Reddy's reported North America generics revenue of $445 million for Q2 FY25, growing 16% year-on-year, per its earnings call. The company has 11 biosimilars in development for global markets, including the US. However, its Q1 FY27 results revealed a 69% year-on-year decline in profit, already under pressure before tariffs were even announced. A 200% tariff on top of existing margin compression would make the US generics business significantly harder.

The Two-Year Window Is the Real Story

The critical detail most investors are overlooking: the tariff starts at 0% in August 2026 and doesn't reach 200% until 2028. That two-year ramp-up is an invitation, not a death sentence. Companies that can establish or scale US manufacturing in that window will not only dodge the tariff — they'll gain a structural advantage over competitors who can't afford to build American plants.

Aurobindo's Dayton facility is already commercially operational. Zydus's California acquisitions give it immediate biologics capacity. These aren't hypothetical hedges; they're revenue-generating assets today.

Meanwhile, the tariff threatens to reshape the competitive landscape itself. Smaller Indian exporters without the capital to build US plants will face an impossible margin squeeze. Market share could consolidate toward the larger players who invested in American manufacturing early — making the survivors stronger, not weaker.

What Retail Investors Should Do

Don't treat the pharma selloff as one trade. Separate the companies with US manufacturing (Aurobindo, Zydus, Cipla) from those exporting finished dosages from India without a local production base. Watch for management commentary on US plant expansion during upcoming Q1 FY27 earnings calls — these will be far more revealing than yesterday's knee-jerk selloff. Sun Pharma's shift to innovative medicines offers a different kind of hedge, since patented drugs face different regulatory treatment than generics. And remember: the two-year ramp means the 200% rate isn't priced into any company's near-term earnings yet. The stocks that dropped 2-6% yesterday may have overreacted — but only for the companies that can actually manufacture on American soil.

Data sourced from company filings on NSE via Xaro.